Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles:
Related suggestion:
Missouri hires Memphis athletic director Laird Veatch for the same role with the TigersNATO newcomer Finland is now a 'frontI'm a female joiner and applied for a job at building firm... but what they said made my blood boilMan City vs Man United FA Cup final time confirmedAbortion returns to the spotlight in Italy 46 years after it was legalizedUkraine, Israel aid package heads to Senate for final approvalPregnant Emily Miller goes braless and shows off her bump under daring tieThe UK pledges $620 million in new military aid for UkraineZendaya puts on a casual display in baggy grey TKevin Costner's ex
2.9312s , 6499.53125 kb
Copyright © 2024 Powered by Chinese inhibitor drug candidate becomes first to enter phase ,World Weaver news portal